MacroGenics Statistics
Total Valuation
MacroGenics has a market cap or net worth of $80.12 million. The enterprise value is -$84.71 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MacroGenics has 63.09 million shares outstanding. The number of shares has increased by 1.12% in one year.
| Current Share Class | 63.09M |
| Shares Outstanding | 63.09M |
| Shares Change (YoY) | +1.12% |
| Shares Change (QoQ) | -0.13% |
| Owned by Insiders (%) | 2.06% |
| Owned by Institutions (%) | 74.24% |
| Float | 52.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.53 |
| Forward PS | 1.55 |
| PB Ratio | 0.68 |
| P/TBV Ratio | 0.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.92, with a Debt / Equity ratio of 0.32.
| Current Ratio | 3.92 |
| Quick Ratio | 3.71 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -99.17 |
Financial Efficiency
Return on equity (ROE) is -49.85% and return on invested capital (ROIC) is -40.64%.
| Return on Equity (ROE) | -49.85% |
| Return on Assets (ROA) | -24.68% |
| Return on Invested Capital (ROIC) | -40.64% |
| Return on Capital Employed (ROCE) | -53.65% |
| Revenue Per Employee | $439,771 |
| Profits Per Employee | -$196,381 |
| Employee Count | 341 |
| Asset Turnover | 0.54 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, MacroGenics has paid $944,000 in taxes.
| Income Tax | 944,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.39% in the last 52 weeks. The beta is 2.22, so MacroGenics's price volatility has been higher than the market average.
| Beta (5Y) | 2.22 |
| 52-Week Price Change | -92.39% |
| 50-Day Moving Average | 2.00 |
| 200-Day Moving Average | 3.24 |
| Relative Strength Index (RSI) | 34.84 |
| Average Volume (20 Days) | 1,078,099 |
Short Selling Information
The latest short interest is 5.62 million, so 8.91% of the outstanding shares have been sold short.
| Short Interest | 5.62M |
| Short Previous Month | 4.97M |
| Short % of Shares Out | 8.91% |
| Short % of Float | 10.74% |
| Short Ratio (days to cover) | 7.77 |
Income Statement
In the last 12 months, MacroGenics had revenue of $149.96 million and -$66.97 million in losses. Loss per share was -$1.07.
| Revenue | 149.96M |
| Gross Profit | -39.53M |
| Operating Income | -110.58M |
| Pretax Income | -136.37M |
| Net Income | -66.97M |
| EBITDA | -103.04M |
| EBIT | -110.58M |
| Loss Per Share | -$1.07 |
Full Income StatementBalance Sheet
The company has $201.67 million in cash and $37.46 million in debt, giving a net cash position of $164.21 million or $2.60 per share.
| Cash & Cash Equivalents | 201.67M |
| Total Debt | 37.46M |
| Net Cash | 164.21M |
| Net Cash Per Share | $2.60 |
| Equity (Book Value) | 116.06M |
| Book Value Per Share | 1.85 |
| Working Capital | 161.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$68.37 million and capital expenditures -$3.71 million, giving a free cash flow of -$72.08 million.
| Operating Cash Flow | -68.37M |
| Capital Expenditures | -3.71M |
| Free Cash Flow | -72.08M |
| FCF Per Share | -$1.14 |
Full Cash Flow StatementMargins
Gross margin is -26.36%, with operating and profit margins of -73.74% and -44.66%.
| Gross Margin | -26.36% |
| Operating Margin | -73.74% |
| Pretax Margin | -44.03% |
| Profit Margin | -44.66% |
| EBITDA Margin | -68.71% |
| EBIT Margin | -73.74% |
| FCF Margin | n/a |
Dividends & Yields
MacroGenics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.12% |
| Shareholder Yield | -1.12% |
| Earnings Yield | -84.24% |
| FCF Yield | -90.67% |
Analyst Forecast
The average price target for MacroGenics is $6.83, which is 437.80% higher than the current price. The consensus rating is "Hold".
| Price Target | $6.83 |
| Price Target Difference | 437.80% |
| Analyst Consensus | Hold |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | -9.96% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MacroGenics has an Altman Z-Score of -4.28 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.28 |
| Piotroski F-Score | 2 |